In its mission to deliver 20 new drugs to the market in a decade, Eli Lilly is looking forward to two new launches in 2022. One is donanemab, a new treatment for Alzheimer’s disease. They have submitted the drug for an accelerated approval and expects to complete its rolling submission by the end of Q1 in 2022 with the hopes of a launch by the end of the year. Secondly is tirzepatide, a drug to treat Type 2 diabetes. They are also hoping for a usage in the treatment of obesity to go along with its FDA approval which would open up a whole new market for the medication.

Click here to view the entire article.